Circulating catecholamines in exercise and hyperventilation induced asthma

P J BARNES, M J BROWN, M SILVERMAN, AND C T DOLLERY

From the Departments of Medicine, Clinical Pharmacology, and Child Health, Hammersmith Hospital, London

ABSTRACT Plasma noradrenaline, adrenaline, and cyclic 3’5’ AMP (cAMP) were measured in seven asthmatic patients with known exercise-induced bronchospasm and six matched non-atopic control subjects during a standard treadmill exercise test and then during matched isocapnic hyperventilation. Normal subjects showed a 5.5 fold rise in noradrenaline and a 3.2 fold rise in adrenaline during exercise compared with a 2.1 fold rise in noradrenaline and no significant rise in adrenaline in asthmatics who all developed bronchoconstriction after exercise (mean fall in peak flow rate 28.4±5.8%). Plasma cAMP rose 1.4 fold in controls but showed no significant rise in asthmatics. This reduced sympathto-adrenal response to exercise in asthmatics is difficult to explain. The failure of circulating catecholamines to rise and stimulate beta adrenoceptors on the mast cell may facilitate the release of bronchoconstrictor mediators. Matched hyperventilation produced bronchospasm in asthmatics (mean fall in peak flow rate 29.0±4.4%) but no change in catecholamines in either group suggesting that circulating catecholamines have no direct role in exercise-induced bronchospasm but may play a permissive role via the mast cell.

Beta-adrenoceptor antagonists such as propranolol cause an increase in bronchial tone in asthmatics but not in normal subjects, suggesting that the airways of asthmatics are under tonic beta-adrenoceptor stimulation. However, intrapulmonary sympathetic innervation of airway smooth muscle has not been demonstrated convincingly in man, and this indicates that pulmonary beta-adrenoceptors may be under the control of circulating catecholamines. Few studies have explored the role of circulating catecholamines in asthma partly because of the difficulties in assaying plasma adrenaline and noradrenaline. Recently, a sensitive and specific radioenzymatic assay has been developed which we have used in the present study.

Exercise induced asthma (EIA) is a well-recognised phenomenon but the mechanism remains uncertain. In normal subjects there is a rise in circulating catecholamine levels during exercise, but it is possible that there may be some abnormality in the catecholamine response to exercise in asthmatics with EIA. It has recently been established that the initiating stimulus in EIA is the temperature and humidity change (heat flux) that occurs in the upper airways as a result of the hyperventilation in exercise, and it is possible to produce similar degrees of bronchoconstriction with matched isocapnic hyperventilation at rest. We therefore compared the plasma catecholamine change occurring in response to exercise and matched hyperventilation in asthmatics with that in non-atopic control subjects.

Methods

Seven male asthmatic patients (all with multiple positive skin tests to common allergens) with known exercise-induced asthma who attended an asthma clinic and six male non-atopic control subjects from a nearby school were studied. There was no significant difference in age, height, weight, or physical fitness between the groups. The mean baseline peak expiratory flow rate (PEFR) of the asthmatics was lower but not significantly different from that of the controls (table 1). Research

Address for reprint requests: Dr Peter Barnes, Department of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0HS.
Table 1  Anthropometric data in asthmatic and control subjects (mean±SEM)

<table>
<thead>
<tr>
<th></th>
<th>Asthmatic patients (n=7)</th>
<th>Control subjects (n=6)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>16.3 ± 0.9</td>
<td>16.5 ± 0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>169 ± 5.3</td>
<td>173 ± 3.5</td>
<td>NS</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>59.9 ± 4.2</td>
<td>60.3 ± 3.7</td>
<td>NS</td>
</tr>
<tr>
<td>PEFR Actual (1 min⁻¹)</td>
<td>396 ± 48</td>
<td>504 ± 48</td>
<td>NS</td>
</tr>
<tr>
<td>Predicted</td>
<td>525 ± 37</td>
<td>546 ± 25</td>
<td>NS</td>
</tr>
</tbody>
</table>

Ethics Committee approval for the study was obtained and all subjects gave informed consent. All asthmatics were asymptomatic at the time of study. None was taking systemic corticosteroids; two asthmatics were taking inhaled salbutamol regularly and one intermittently. All medication was stopped at least 12 hours before study. All subjects were tested at the same time of day.

A small cannula was inserted into a forearm vein and the subject rested for 30 minutes. Blood (5 ml) was withdrawn into a prechilled tube with 0.1% M EDTA, centrifuged at 4°C and the plasma frozen (−80°C). Plasma adenine and noradrenaline were measured by a radioenzymatic method with a sensitivity of 0.06 nmol/l and within-assay coefficient of variation of 3.5%. Plasma cyclic 3′5′ AMP (cAMP) was measured by a competitive protein binding assay (Amersham Kit TRK 432). PEFR was measured using a Wright Peak Flow Meter and heart rate recorded electrocardiographically. Each subject then performed a standard exercise test on a treadmill with a slope of six degrees at six kph for six minutes. Blood was sampled and PEFR measured during the last minute of exercise. During the exercise subjects wore a nose clip and breathed through a low resistance mobile valve. Inspired minute ventilation was measured by a dry gas meter (Parkinson Cowan CD4), expired gas was continuously sampled for CO₂ (Godart infra red analyser) and recorded by ink jet chart recorder (Mingograf 81). After exercise the subject sat and PEFR was recorded at one minute, then blood sampled and PEFR recorded at five, 15, and 30 minutes.

Subjects rested for at least two hours to avoid the refractory period during which a second exercise test causes less bronchospasm, and then performed a voluntary hyperventilation test. After baseline blood samples had been taken, subjects hyperventilated while seated to achieve a "target" minute ventilation which was identical to that recorded during exercise. The target consisted of an electrically driven revolving pointer fixed over the dial of the gas meter. End-tidal CO₂ was adjusted to that measured during the exercise test by adding 100% CO₂ to the inspired air. Subjects hyperventilated for six minutes and blood was sampled during the last minute. PEFR was recorded at the end of hyperventilation again one minute later. Blood samples and PEFR measured were taken at five, 15, and 30 minutes after hyperventilation.

Results were analysed by Student's t test. All results show mean with standard errors.

Results

There was no significant difference between the asthmatic and non-atopic subjects in either maximum minute ventilation or in heart rate increase during exercise (table 2). There was no significant change in PEFR of controls during or after exercise but in asthmatics, after a small rise during exercise there was a fall in PEFR of 29.4±5.8% five minutes after exercise, and return to baseline values 25 minutes later (fig 1).

There was no significant difference between baseline plasma adrenaline, noradrenaline, or cAMP between the two groups (table 3). In control subjects there was a 5.5 fold rise in noradrenaline and 3.2 fold rise in adrenaline during exercise. However, in asthmatics noradrenaline rose 2.1 fold and there was no significant rise in adrenaline (fig 1). Plasma cAMP rose 1.4 fold in controls but showed no significant rise in asthmatics (fig 2). The difference in response between groups was significant (p<0.001) for adrenaline, noradrenaline, and cAMP.

With hyperventilation there was no significant change in PEFR in controls but a mean fall of 29.0±5.4% after five minutes in asthmatics. In each individual the fall in PEFR with matched hyperventilation was similar to the fall after exercise. There was no significant change in plasma adrenaline, noradrenaline or cAMP during hyperventilation in either asthmatics or controls. Nor was there any significant rise in adrenaline or nor-

Table 2  Heart rate and ventilation response to exercise in asthmatic patients and control subjects (mean±SEM)

<table>
<thead>
<tr>
<th></th>
<th>Asthmatic patients</th>
<th>Control subjects</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting heart rate (min⁻¹)</td>
<td>77.7 ± 3.5</td>
<td>71.6 ± 4.8</td>
<td>NS</td>
</tr>
<tr>
<td>Maximum heart rate during exercise (min⁻¹)</td>
<td>162.7 ± 1.4</td>
<td>155.8 ± 3.9</td>
<td>NS</td>
</tr>
<tr>
<td>Maximum ventilation during exercise (1 min⁻¹)</td>
<td>46.0 ± 2.4</td>
<td>53.9 ± 3.5</td>
<td>NS</td>
</tr>
</tbody>
</table>
Circulating catecholamines in exercise and hyperventilation induced asthma

Fig 1 Changes in PEFR and plasma catecholamines with exercise in seven asthmatic patients (●) and six control subjects (○). Results show mean±SEM. ** = p < 0.001, * = p < 0.05.

Fig 2 Changes in plasma cyclic AMP with exercise in seven asthmatic patients (●) and six control subjects (○). ** = p < 0.001.

Fig 3 Changes in PEFR and plasma catecholamines with voluntary hyperventilation in seven asthmatic patients (●) and six control subjects (○).
adrenaline during the period of maximum bronchoconstriction after hyperventilation (table 4, fig 3).

Discussion

All subjects exercised at the same work load and had a similar ventilatory and circulatory response, yet there was a marked difference in catecholamine response between asthmatic and non-atopic control subjects. In controls plasma adrenaline rose three-fold during exercise but in asthmatics there was no significant rise, while plasma noradrenaline showed a five-fold rise in controls but only a two-fold rise in asthmatics. This impaired catecholamine response to exercise in asthmatics with exercise-induced asthma is difficult to explain. Bronchodilator medication is unlikely to be responsible for the difference since only three of the asthmatics were taking beta-adrenergic treatment. Moreover salbutamol, when given either orally or by inhalation has had no significant effect on circulating catecholamines in normal subjects (unpublished observations). Circulating noradrenaline is derived mainly from overspill from adrenergic nerves, and since the sympathetic innervation of human lung is relatively insignificant, it is unlikely that the difference between asthmatics and normal subjects reflects any difference in pulmonary sympathetic innervation. Plasma adrenaline is derived solely from the adrenal medulla. It is possible that the difference is caused by increased clearance of catecholamines in asthmatics. This seems unlikely, since baseline values are not significantly different from the normal subjects and infused adrenaline in asthmatics shows a similar clearance to that in normal subjects (unpublished observations). These results therefore imply a generalised defect in the sympatho-adrenal response to exercise in asthmatics who develop EIA. The impaired rise in plasma cAMP during exercise in asthmatics is correlated with the absent rise in circulating adrenaline.

These findings are at variance with other studies which report either no difference in catecholamines during exercise between asthmatic and normal subjects, or an exaggerated rise during exercise. However, in these studies the work load was higher and plasma catecholamines were measured by fluorimetric methods which are relatively insensitive and non-specific in estimating circulating catecholamines. Other studies have shown an impaired rise in free fatty acids after exercise and an impaired rise in plasma cyclic AMP during exercise in asthmatics, which would be consistent with an impaired sympatho-adrenal response to exercise in asthmatics.

Is the impaired catecholamine response in asthmatics specific for exercise? Mathé and Knapp demonstrated an impaired catecholamine response to mental stress in asthmatics. Insulin tolerance tests in asthmatics provoke a normal hyperglycaemia-induced increase in plasma adrenaline, however, suggesting that the sympatho-adrenal...
Circulating catecholamines in exercise and hyperventilation induced asthma

439

defect may be specific for exercise (unpublished observations).

It is possible that this impaired sympathetic-adrenal response to exercise could be important in the pathophysiology of exercise-induced bronchoconstriction. Stimulation of beta-adrenoceptors on pulmonary mast cells inhibits the release of bronchoconstrictor mediators such as histamine and slow-reacting substance of anaphylaxis.\textsuperscript{22, 23} The impaired rise in circulating catecholamines in asthmatics may therefore make release of mediators more likely to occur. It is also possible that the small noradrenaline rise in asthmatics in the absence of a rise in adrenaline may stimulate alpha-adrenoceptors on mast cells causing increased mediator release.\textsuperscript{24} In support of this, it has been shown that arterial histamine levels rise during exercise in asthmatics but not in normal subjects.\textsuperscript{25}

Voluntary hyperventilation caused a similar bronchoconstriction response to the exercise stimulus in asthmatic subjects, yet there was no significant change in circulating catecholamines. This makes it unlikely that circulating catecholamines control bronchial tone directly but it is possible that hyperventilation causes release of mediators from sensitised pulmonary mast cells, which are not protected by a rise in circulating catecholamines.

The reduced sympathetic-adrenal response to exercise in asthmatics with EIA, although difficult to explain, may play a role in the pathogenesis of bronchoconstriction by a permissive action on the mast cell.

We are grateful to Marion Tooley for technical assistance. This work was supported by Medical Research Council Program Grant G971/16/C.

References


22. Orange RP, Kaliner MA, Laraia PJ, Austen KF. Immunological release of histamine and slow re-

23 Tomita Y, Patterson R, Suszko IM. Respiratory mast cells and basophiloid cells. II. Effect on 3'5' adenosine monophosphate content and on antigen-induced histamine release. Int Arch Allergy Appl Immunol 1974; 47:261-72.


acting substance of anaphylaxis from human lung.